Veracyte aims to ride a wave of growing use of newer, less invasive cancer tests, with a steady stream of upcoming launches that could broaden it beyond its best-known products. The catch is that success depends on doctors and insurers backing these tests, while bigger rivals and tighter rules could squeeze growth and profits.Read more
Veracyte could grow faster than many expect as more doctors use its cancer tests and the company expands into new markets overseas. But its future also depends heavily on a small number of flagship tests, and rising pressure from insurers and competitors could squeeze pricing and slow adoption.Read more
Veracyte sells genetic tests that help doctors make treatment decisions, but tougher insurance rules and pricing pressure could make it harder to grow and keep profits steady. At the same time, cheaper AI-based diagnostic tools may narrow the gap with rivals and weaken the company’s ability to charge premium prices.Read more
No trending discussion available.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
